Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies

Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies

Abstract Background When epidermal growth factor receptor (EGFR) gene mutation-positive non-small cell lung cancer (NSCLC) acquires resistance to the initial tyrosine kinase inhibitor (TKI) treatment, reassessing the tumor DNA by re-biopsy is essential for further treatment selection. However, the p...

Full description

Bibliographic Details
Main Authors: Sakurako Uozu, Kazuyoshi Imaizumi, Teppei Yamaguchi, Yasuhiro Goto, Kenji Kawada, Tomoyuki Minezawa, Takuya Okamura, Ken Akao, Masamichi Hayashi, Sumito Isogai, Mitsushi Okazawa, Naozumi Hashimoto, Yoshinori Hasegawa
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Pulmonary Medicine
Subjects:
Re-biopsy
Molecular targeted therapy
EGFR-TKI
Metastasis
Retrospective analysis
Bronchoscopy
Online Access:http://link.springer.com/article/10.1186/s12890-017-0514-3

Internet

http://link.springer.com/article/10.1186/s12890-017-0514-3

Similar Items